オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - susoctocog alfa, quantity: 500 u/ml - injection - excipient ingredients: - for the treatment of bleeding episodes in adults with acquired haemophilia a.,safety and efficacy of obizur have not been established in patients with baseline anti- porcine factor viii inhibitor titre greater than 20 bu.,obizur is not indicated for the treatment of congenital haemophilia a or von willebrand disease.

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

abbvie limited - dexamethasone 700ug - intraocular implant - 700 mcg - active: dexamethasone 700ug excipient: polyglactin (poly (d, l-lactide-co-glycolide), 50:50 plga acid) polyglactin - ozurdex® is indicated for the treatment of macular oedema due to retinal vein occlusion (rvo).

イスラエル - 英語 - Ministry of Health

abbvie biopharmaceuticals ltd, israel - dexamethasone - implant in applicator - dexamethasone 0.7 mg - dexamethasone - dexamethasone - ozurdex is indicated for the treatment of adult patients with:• diabetic macular oedema (dme)• macular oedema following either branch retinal vein occlusion (brvo) or central retinal vein occlusion (crvo).• inflammation of the posterior segment of the eye presenting as non-infectious uveitis.

欧州連合 - 英語 - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - dexamethasone - macular edema; uveitis - ophthalmologicals, other ophthalmologicals - ozurdex is indicated for the treatment of adult patients with macular oedema following either branch retinal-vein occlusion (brvo) or central retinal-vein occlusion (crvo).ozurdex is indicated for the treatment of adult patients with inflammation of the posterior segment of the eye presenting as noninfectious uveitis.ozurdex is indicated for the treatment of adult patients with visual impairment due to diabetic macular oedema (dme) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy.

欧州連合 - 英語 - EMA (European Medicines Agency)

grünenthal gmbh - lesinurad - hyperuricemia - antigout preparations - zurampic, in combination with a xanthine oxidase inhibitor, is indicated in adults for the adjunctive treatment of hyperuricaemia in gout patients (with or without tophi) who have not achieved target serum uric acid levels with an adequate dose of a xanthine oxidase inhibitor alone.,

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

allergan, inc. - dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - dexamethasone 0.7 mg - ozurdex ®   (dexamethasone intravitreal implant) is indicated for the treatment of macular edema following branch retinal vein occlusion (brvo) or central retinal vein occlusion (crvo). ozurdex ®   is indicated for the treatment of non-infectious uveitis affecting the posterior segment of the eye. ozurdex ®   is indicated for the treatment of diabetic macular edema.   ozurdex ®   (dexamethasone intravitreal implant) is contraindicated in patients with active or suspected ocular or periocular infections including most viral diseases of the cornea and conjunctiva, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases.  ozurdex ® is contraindicated in patients with glaucoma, who have cup to disc ratios of greater than 0.8. ozurdex ® is contraindicated in patients whose posterior lens capsule is torn or ruptured because of the risk of migration into the anterior chamber. laser posterior capsulotomy in pseudophakic pati

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

kadmon pharmaceuticals, llc - belumosudil (unii: 834yjf89wo) (belumosudil - unii:834yjf89wo) - rezurock is indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic gvhd) after failure of at least two prior lines of systemic therapy. none. risk summary based on findings from animal studies and the mechanism of action [see clinical pharmacology (12.1)] , rezurock can cause fetal harm when administered to pregnant women. there are no available human data on rezurock use in pregnant women to evaluate for a drug-associated risk. in animal reproduction studies, administration of belumosudil to pregnant rats and rabbits during the period of organogenesis resulted in adverse developmental outcomes, including alterations to growth, embryo-fetal mortality, and embryo-fetal malformations at maternal exposures (auc) approximately ≥3- (rat) and ≥0.07 (rabbit) times the human exposure (auc) at the recommended dose (see data) . advise pregnant women and females of reproductive potential of the potential risk to the fetus. in the u.s. general popula

オーストラリア - 英語 - APVMA (Australian Pesticides and Veterinary Medicines Authority)

max(rudong) chemicals co., ltd. - thidiazuron - unknown - thidiazuron uron active 0.0 - active constituent

オーストラリア - 英語 - APVMA (Australian Pesticides and Veterinary Medicines Authority)

australis crop protection pty ltd - thidiazuron - suspension concentrate - thidiazuron uron active 500.0 g/l - growth regulator - cotton - pre harvest | except crop-seed production - defoliation of cotton plants | defoliation aid

オーストラリア - 英語 - APVMA (Australian Pesticides and Veterinary Medicines Authority)

conquest crop protection pty ltd - thidiazuron - suspension concentrate - thidiazuron uron active 500.0 g/l - growth regulator - cotton - pre-harvest - defoliation of cotton plants | defoliation aid